Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Asieris Approved to Start Global Phase III Trials of Cervical Lesion Treatment

publication date: Jul 8, 2020

Asieris Pharma, a Taizhou biotech, received China approval to start a Phase III trial of Cevira®, a photodynamic drug-device combination that offers a non-surgical treatment for cervical lesions. The company is starting a multi-centered global Phase III trial of the product with trials in the US and EU in addition to China. One year ago, Asieris in-licensed global rights to Cevira® from Photocure of Oslo in an agreement worth up to $73 million. Asieris focuses on novel treatments for genitourinary tumors. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021